ClinicalTrials.gg
RecruitingNCT05369351Updated Oct 20, 2026

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

A Phase 2 interventional study of Standard treatment+mirabegron and Standard treatment in Intracerebral Haemorrhage, sponsored by Tianjin Medical University General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Tianjin Medical University General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 20, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
71st of 77
25 · median 180
Started
2024
with 12 others
Phase 2
13 of 123
5 open now
Primary completion
2027-08
later than 32 of 61 live
Registered
54th of 123
by date

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 71st largest by planned enrollment of the 77 interventional ones that give a count, is one of 13 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 32 of the 61 other live ones, and was the 54th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.

Read the detailed description

This study is to evaluate the efficacy and safety of mirabegron in patients with intracerebral hemorrhage based on standard therapy

03

Conditions studied

  • Intracerebral Haemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged above 18 years old.
  2. The volume of the hematoma is 5-30 ml (including the cerebral cortex; Putamen, thalamus, caudate nucleus and related deep tracts; Cerebellar hemorrhage), which determined by CT scan.
  3. The onset of cerebral hemorrhage symptoms or the time from last normal to detection is not more than 72 hours.
  4. Patients with Glasgow Coma Scale (GCS) score ≥6 and \< 12.
  5. Before the onset of the disease, function was independent and mRS score\<1.
  6. Able and willing to sign written and comply with the requirements of the research protocol.

Exclusion criteria

Exclusion criteria:

  1. Multifocal cerebral hemorrhage, brain stem hemorrhage, or ventricular hemorrhage.
  2. Secondary cerebral hemorrhage caused by aneurysm, brain tumor, arteriovenous malformation, thrombocytopenia, coagulation disorder, traumatic brain injury, etc.
  3. Patients who require hematoma removal surgery or other emergency surgical interventions (such as decompressive craniectomy), or who are critically ill and close to death.
  4. Patients who interfere with drug use due to nausea or vomiting.
  5. Combined with the following conditions that preclude participation in the study due to other systemic diseases: Severe hepatic or renal impairment, atrial fibrillation or tachycardia, pulmonary infection, severe urinary tract infection, severe urinary tract obstruction, medically uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg), pregnant and lactating women, and a history of malignant tumors within 5 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Standard treatment+mirabegron

    In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.

    Drug: Standard treatment+mirabegron

  • Other
    Standard treatment

    Patients will receive usual care

    Other: Standard treatment

Interventions

  • DrugStandard treatment+mirabegron

    Drug page: MirabegronStudies of MirabegronMirabegron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.

  • OtherStandard treatment

    Standard treatment

06

What researchers measure

Primary outcomes

  1. Changes in absolute perihematomal edema volume measured by computed tomography (CT)

    Repeated CT images will be obtained at 24-48 hours after diagnosis and on days 7 and 14 with CT at 24-48 hours after diagnosis as the baseline for analysis.

    Time frame: 7 and 14 days

Secondary outcomes

  1. Changes in absolute hematoma volume measured by CT after ICH

    Repeated CT images will be obtained at 24-48 hours after diagnosis and on days 7 and 14 with CT at 24-48 hours after diagnosis as the baseline for analysis.

    Time frame: 7 and 14 days

  2. Changes in NIHSS scores

    The assessment will be based on the National Institutes of Health Stroke Scale (NIHSS) with a score range of 0 (asymptomatic) to 42 (death).

    Time frame: 7 and 14 days

  3. The rate of functional independence at 90 days

    Number of participants with functional independence. Modified Rankin scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes neurological disability. Functional Independence: 0 - no symptoms at all 1 - no significant disability despite symptoms; able to carry out all usual duties and activities 2- slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance

    Time frame: 90 days

  4. Proportion of adverse drug reactions

    Adverse events related to mirabegron will be recorded.

    Time frame: 14 days

  5. All cause mortality

    Death induced by any cause

    Time frame: 90 days

  6. Changes of immune cells in peripheral blood

    The counts of monocytes subsets and other immune cells in peripheral blood were compared.

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 42 months after the start.

Of 24 phase 2 interventional studies under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 42 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Aug 2026 → Aug 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 11, 2022
StartActual
Jan 17, 2024
Primary completionEst.
Aug 10, 2027was Aug 2026
CompletionEst.
Nov 10, 2027was Nov 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Tianjin Medical University General Hospital · Tianjin, China
Show 1 removed
  • Tianjin Medical University General Hospital · Tianjin, China
Oct 20, 2026
Primary completion
Aug 10, 2026→Aug 10, 2027
Oct 20, 2026
Study completion
Nov 10, 2026→Nov 10, 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site added, 1 site removed
    Show site
    • Tianjin Medical University General Hospital · Tianjin, China
    Show 1 removed
    • Tianjin Medical University General Hospital · Tianjin, China
    Primary completion Aug 10, 2026→Aug 10, 2027
    Study completion Nov 10, 2026→Nov 10, 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05369351
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Qiang Liu (Professor of Neurology Department, Tianjin Medical University General Hospital) — Principal investigator
First posted
May 11, 2022
Start date
Jan 17, 2024
Primary completion
Aug 10, 2027 (estimated)
Completion
Nov 10, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Handong Li
Contact
handongli90@foxmail.com
+8615022439149

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirabegron

Start the discussion